{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:55:49Z","timestamp":1794048949981,"version":"4.8.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.gastha.2023.09.013","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T12:21:15Z","timestamp":1696594875000},"page":"344-352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Farnesoid X Receptor Agonists: A Promising Therapeutic Strategy for Gastrointestinal Diseases"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5503-2371","authenticated-orcid":false,"given":"Mohammad","family":"Almeqdadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredric D.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastha.2023.09.013_bib1","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.3390\/cells10113206","article-title":"The pathophysiology of farnesoid X receptor (FXR) in the GI tract: inflammation, barrier function and innate immunity","volume":"10","author":"Anderson","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.gastha.2023.09.013_bib2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/aps.2014.116","article-title":"Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis","volume":"36","author":"Jiao","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.gastha.2023.09.013_bib3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab"},{"key":"10.1016\/j.gastha.2023.09.013_bib4","doi-asserted-by":"crossref","first-page":"G923","DOI":"10.1152\/ajpgi.00490.2005","article-title":"Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-\u03b1\/\u03b2 in the adaptive response to bile acids","volume":"290","author":"Zollner","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.gastha.2023.09.013_bib5","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1053\/jhep.2002.31724","volume":"35","author":"Plass","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2023.09.013_bib6","doi-asserted-by":"crossref","first-page":"G476","DOI":"10.1152\/ajpgi.00430.2005","article-title":"The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-\u03b1 and -\u03b2 genes","volume":"290","author":"Landrier","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.gastha.2023.09.013_bib7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1053\/gast.2001.25503","article-title":"The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp","volume":"121","author":"Denson","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2023.09.013_bib8","doi-asserted-by":"crossref","first-page":"19909","DOI":"10.1074\/jbc.M207903200","article-title":"Liver receptor homologue-1 mediates species- and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter","volume":"278","author":"Chen","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.gastha.2023.09.013_bib9","doi-asserted-by":"crossref","DOI":"10.1621\/nrs.08005","article-title":"Deciphering the nuclear bile acid receptor FXR paradigm","volume":"8","author":"Modica","year":"2010","journal-title":"Nucl Recept Signal"},{"key":"10.1016\/j.gastha.2023.09.013_bib10","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3390\/cells10061281","article-title":"Bile acids activated receptors in inflammatory bowel disease","volume":"10","author":"Biagioli","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.gastha.2023.09.013_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1065790","article-title":"Stimulation of the farnesoid X receptor promotes M2 macrophage polarization","volume":"14","author":"Jaroonwitchawan","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.gastha.2023.09.013_bib12","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3389\/fimmu.2018.01853","article-title":"Bile acids activated receptors regulate innate immunity","volume":"9","author":"Fiorucci","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.gastha.2023.09.013_bib13","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.4049\/jimmunol.0901347","article-title":"The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis","volume":"183","author":"Mencarelli","year":"1950","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.gastha.2023.09.013_bib14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/bmb\/ldaa006","article-title":"Obeticholic acid\u2014a new therapy in PBC and NASH","volume":"133","author":"Chapman","year":"2020","journal-title":"Br Med Bull"},{"key":"10.1016\/j.gastha.2023.09.013_bib15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-pathol-020712-164014","article-title":"The immunobiology and pathophysiology of primary biliary cirrhosis","volume":"8","author":"Hirschfield","year":"2013","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.gastha.2023.09.013_bib16","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2023.09.013_bib17","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s12072-017-9830-1","article-title":"Primary biliary cholangitis: a comprehensive overview","volume":"11","author":"Lleo","year":"2017","journal-title":"Hepatol Int"},{"key":"10.1016\/j.gastha.2023.09.013_bib18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2023.09.013_bib19","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1080\/00365521.2019.1669702","article-title":"Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy","volume":"54","author":"Vespasiani-Gentilucci","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gastha.2023.09.013_bib20","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ueg2.12095","article-title":"Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease","volume":"9","author":"Cortez-Pinto","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.gastha.2023.09.013_bib21","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gastha.2023.09.013_bib22","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A\u00a0randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2023.09.013_bib23","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2468-1253(19)30094-9","article-title":"Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study","volume":"4","author":"Trauner","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2023.09.013_bib24","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.cgh.2019.09.050","article-title":"Long-term obeticholic acid therapy improves histological endpoints in patients with primary biliary cholangitis","volume":"18","author":"Bowlus","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2023.09.013_bib25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jhep.2020.07.028","article-title":"Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis","volume":"74","author":"Kj\u00e6rgaard","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2023.09.013_bib26","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/liv.14429","article-title":"Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis","volume":"40","author":"Par\u00e9s","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.gastha.2023.09.013_bib27","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.gastha.2023.09.013_bib28","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.gastha.2023.09.013_bib29","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2023.09.013_bib30","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.gastha.2023.09.013_bib31","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jhep.2022.10.023","article-title":"Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH","volume":"78","author":"Ratziu","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2023.09.013_bib32","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A\u00a0randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2023.09.013_bib33","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2023.09.013_bib35","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/hep.31017","article-title":"Liver injury in patients with cholestatic liver disease treated with obeticholic acid","volume":"71","author":"Eaton","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2023.09.013_bib36","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/hep.32117","article-title":"Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases","volume":"75","author":"Lindor","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2023.09.013_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172661","article-title":"Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis","volume":"863","author":"Venetsanaki","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.gastha.2023.09.013_bib39","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2023.09.013_bib40","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41598-023-28647-4","article-title":"Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH","volume":"13","author":"Marchian\u00f2","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.gastha.2023.09.013_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100324","article-title":"Liver-specific FGFR4 knockdown in mice on an HFD increases bile acid synthesis and improves hepatic steatosis","volume":"64","author":"Moreau","year":"2023","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.gastha.2023.09.013_bib42","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1002\/ptr.7770","article-title":"Deoxyschizandrin ameliorates obesity and non-alcoholic fatty liver disease: involvement of dual Farnesyl X receptor\/G protein-coupled bile acid receptor 1 activation and leptin sensitization","volume":"37","author":"Gu","year":"2023","journal-title":"Phytother Res"},{"key":"10.1016\/j.gastha.2023.09.013_bib43","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.yexcr.2018.11.023","article-title":"Bile acid-induced apoptosis and bile acid synthesis are reduced by over-expression of Augmenter of Liver Regeneration (ALR) in a STAT3-dependent mechanism","volume":"374","author":"Ibrahim","year":"2019","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.gastha.2023.09.013_bib44","series-title":"Protein kinase-mediated decisions between life and Death.Vol 1275. Advances in experimental medicine and biology","first-page":"229","article-title":"Bile acid toxicity and protein kinases","author":"Engin","year":"2021"},{"key":"10.1016\/j.gastha.2023.09.013_bib45","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3390\/microorganisms3040641","article-title":"The gut microbiota as a therapeutic target in IBD and metabolic disease: a role for the bile acid receptors FXR and TGR5","volume":"3","author":"Baars","year":"2015","journal-title":"Microorganisms"},{"key":"10.1016\/j.gastha.2023.09.013_bib46","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1038\/s41598-020-58644-w","article-title":"Attenuation of bile acid-mediated FXR and PXR activation in patients with Crohn's disease","volume":"10","author":"Wilson","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.gastha.2023.09.013_bib47","doi-asserted-by":"crossref","first-page":"4822","DOI":"10.1039\/D2BM00559J","article-title":"Mesenchymal stem cell-derived exosome mitigates colitis via the modulation of the gut metagenomics\u2013metabolomics\u2013farnesoid X receptor axis","volume":"10","author":"Ocansey","year":"2022","journal-title":"Biomater Sci"},{"key":"10.1016\/j.gastha.2023.09.013_bib48","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13099-022-00499-9","article-title":"The gut metagenomics and metabolomics signature in patients with inflammatory bowel disease","volume":"14","author":"Xu","year":"2022","journal-title":"Gut Pathog"},{"key":"10.1016\/j.gastha.2023.09.013_bib49","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.4049\/jimmunol.0803978","article-title":"The bile acid receptor FXR is a modulator of intestinal innate immunity","volume":"183","author":"Vavassori","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.gastha.2023.09.013_bib50","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/gut.2010.212159","article-title":"Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease","volume":"60","author":"Gadaleta","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.gastha.2023.09.013_bib51","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/cr.2008.289","article-title":"FXR: a metabolic regulator and cell protector","volume":"18","author":"Wang","year":"2008","journal-title":"Cell Res"},{"key":"10.1016\/j.gastha.2023.09.013_bib52","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1194\/jlr.M069807","article-title":"Cholesterol 7\u03b1-hydroxylase protects the liver from inflammation and fibrosis by maintaining cholesterol homeostasis","volume":"57","author":"Liu","year":"2016","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.gastha.2023.09.013_bib53","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.3390\/ijms22083807","article-title":"Obeticholic acid derivative, T-2054 suppresses osteoarthritis via inhibiting NF-\u03baB-Signaling pathway","volume":"22","author":"Guo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.gastha.2023.09.013_bib54","doi-asserted-by":"crossref","first-page":"13850","DOI":"10.1074\/jbc.M112.443937","article-title":"SUMOylation of the farnesoid X receptor (FXR) regulates the expression of FXR target genes","volume":"288","author":"Balasubramaniyan","year":"2013","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.gastha.2023.09.013_bib55","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.ajpath.2013.08.011","article-title":"Critical role of FoxO3a in alcohol-induced autophagy and hepatotoxicity","volume":"183","author":"Ni","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.gastha.2023.09.013_bib56","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbrc.2013.11.057","article-title":"Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease","volume":"443","author":"Wu","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.gastha.2023.09.013_bib57","doi-asserted-by":"crossref","first-page":"G892","DOI":"10.1152\/ajpgi.00575.2007","article-title":"Involvement of mammalian sirtuin 1 in the action of ethanol in the liver","volume":"294","author":"You","year":"2008","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.gastha.2023.09.013_bib58","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.redox.2014.08.007","article-title":"Farnesoid X receptor regulates forkhead Box O3a activation in ethanol-induced autophagy and hepatotoxicity","volume":"2","author":"Manley","year":"2014","journal-title":"Redox Biol"},{"key":"10.1016\/j.gastha.2023.09.013_bib59","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cbi.2014.03.014","article-title":"The FXR agonist 6ECDCA reduces hepatic steatosis and oxidative stress induced by ethanol and low-protein diet in mice","volume":"217","author":"L\u00edvero","year":"2014","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.gastha.2023.09.013_bib60","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1194\/jlr.M039404","article-title":"Regulation of human class I alcohol dehydrogenases by bile acids","volume":"54","author":"Langhi","year":"2013","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.gastha.2023.09.013_bib61","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1053\/j.gastro.2014.01.020","article-title":"Interactions between the intestinal microbiome and liver diseases","volume":"146","author":"Schnabl","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2023.09.013_bib62","doi-asserted-by":"crossref","first-page":"237","DOI":"10.5009\/gnl.2014.8.3.237","article-title":"Host-microbiome interactions in alcoholic liver disease","volume":"8","author":"Chen","year":"2014","journal-title":"Gut Liver"},{"key":"10.1016\/j.gastha.2023.09.013_bib63","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4291\/wjgp.v5.i4.514","article-title":"Alterations of the gut microbiome and metabolome in alcoholic liver disease","volume":"5","author":"Zhong","year":"2014","journal-title":"World J Gastrointest Pathophysiol"},{"key":"10.1016\/j.gastha.2023.09.013_bib64","first-page":"30","article-title":"Jejunal microflora in patients with chronic alcohol abuse","volume":"31","author":"Bode","year":"1984","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.gastha.2023.09.013_bib65","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/hep.24018","article-title":"Enteric dysbiosis associated with a mouse model of alcoholic liver disease","volume":"53","author":"Yan","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2023.09.013_bib66","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s10620-013-2960-y","article-title":"The impact of alcohol consumption and cholecystectomy on small intestinal bacterial overgrowth","volume":"59","author":"Gabbard","year":"2014","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastha.2023.09.013_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053028","article-title":"Metagenomic analyses of alcohol induced pathogenic alterations in\u00a0the intestinal microbiome and the effect of lactobacillus rhamnosus GG treatment","volume":"8","author":"Bull-Otterson","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.gastha.2023.09.013_bib68","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/hep.23009","article-title":"Endotoxemia and gut barrier dysfunction in alcoholic liver disease","volume":"50","author":"Rao","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2023.09.013_bib69","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1096\/fj.13-231860","article-title":"Alteration of bile acid metabolism in the rat induced by chronic ethanol consumption","volume":"27","author":"Xie","year":"2013","journal-title":"FASEB J"},{"key":"10.1016\/j.gastha.2023.09.013_bib70","first-page":"5","article-title":"Recent advances in the development of farnesoid X receptor agonists","volume":"3","author":"Ali","year":"2015","journal-title":"Ann Transl Med"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572323001590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572323001590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T19:02:09Z","timestamp":1714676529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772572323001590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"alternative-id":["S2772572323001590"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2023.09.013","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Farnesoid X Receptor Agonists: A Promising Therapeutic Strategy for Gastrointestinal Diseases","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2023.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}